English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/96178
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 10 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar EndNote (RIS)Exportar EndNote (RIS)
Título

Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: Two relevant therapeutic targets for neurological disorders

Autor Morales-García, José A. ; Palomo Ruiz, Valle; Redondo, Miriam ; Alonso-Gil, Sandra ; Gil, Carmen ; Martínez, Ana ; Pérez Castillo, Ana
Palabras clave GSK-3
PDE7
Dual GSK-3/PDE7 inhibitors
Neuroinflammation
Fecha de publicación 2014
EditorAmerican Chemical Society
Citación ACS Chemical Neuroscience 5(3): 194-204 (2014)
ResumenChronic neuroinflammation has been increasingly recognized as a primary mechanism underlying acute brain injury and neurodegenerative diseases. Enhanced expression of diverse pro-inflammatory agents in glial cells has been shown to contribute to the cell death that takes place in these disorders. Previous data from our group have shown that different inhibitors of the cyclic adenosine monophosphate (cAMP) specific phosphodiesterase 7 (PDE7) and glycogen synthase kinase-3 (GSK-3) enzymes are potent anti-inflammatory agents in different models of brain injury. In this study, we investigated cross-talk between PDE7 and GSK-3, two relevant therapeutic targets for neurological disorders, using a chemical approach. To this end, we compared specific inhibitors of GSK-3 and PDE7 with dual inhibitors of both enzymes with regard to anti-inflammatory effects in primary cultures of glial cells treated with lipopolysaccharide. Our results show that the GSK-3 inhibitors act exclusively by inhibition of this enzyme. By contrast, PDE7 inhibitors exert their effects via inhibition of PDE7 to increase intracellular cAMP levels but also through indirect inhibition of GSK-3. Activation of protein kinase A by cAMP results in phosphorylation of Ser9 of GSK-3 and subsequent inhibition. Our results indicate that the indirect inhibition of GSK-3 by PDE7 inhibitors is an important mechanism that should be considered in the future development of pharmacological treatments. © 2014 American Chemical Society.
URI http://hdl.handle.net/10261/96178
DOI10.1021/cn400166d
Identificadoresdoi: 10.1021/cn400166d
issn: 1948-7193
e-issn: 1948-7193
Aparece en las colecciones: (IIBM) Artículos
(IQM) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.